Literature DB >> 21169546

Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Thomas S Griffith1, Erik L Brincks, Prajwal Gurung, Tamara A Kucaba, Thomas A Ferguson.   

Abstract

Systemic immunological tolerance to Ag encountered in the eye restricts the formation of potentially damaging immune responses that would otherwise be initiated at other anatomical locations. We previously demonstrated that tolerance to Ag administered via the anterior chamber (AC) of the eye required Fas ligand-mediated apoptotic death of inflammatory cells that enter the eye in response to the antigenic challenge. Moreover, the systemic tolerance induced after AC injection of Ag was mediated by CD8(+) regulatory T cells. This study examined the mechanism by which these CD8(+) regulatory T cells mediate tolerance after AC injection of Ag. AC injection of Ag did not prime CD4(+) T cells and led to increased TRAIL expression by splenic CD8(+) T cells. Unlike wild-type mice, Trail(-/-) or Dr5(-/-) mice did not develop tolerance to Ag injected into the eye, even though responding lymphocytes underwent apoptosis in the AC of the eyes of these mice. CD8(+) T cells from Trail(-/-) mice that were first injected via the AC with Ag were unable to transfer tolerance to naive recipient wild-type mice, but CD8(+) T cells from AC-injected wild-type or Dr5(-/-) mice could transfer tolerance. Importantly, the transferred wild-type (Trail(+/+)) CD8(+) T cells were also able to decrease the number of infiltrating inflammatory cells into the eye; however, Trail(-/-) CD8(+) T cells were unable to limit the inflammatory cell ingress. Together, our data suggest that "helpless" CD8(+) regulatory T cells generated after AC injection of Ag enforce systemic tolerance in a TRAIL-dependent manner to inhibit inflammation in the eye.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169546      PMCID: PMC3075597          DOI: 10.4049/jimmunol.1002678

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations.

Authors:  G A Wilbanks; J W Streilein
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

2.  Isolation and characterization of an antigen-specific suppressor inducer molecule from serum of hyperimmune mice by using a monoclonal antibody.

Authors:  T A Ferguson; G M Iverson
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

3.  The differing patterns of antigen release and local retention following anterior chamber and intravenous inoculation of soluble antigen. Evidence that the eye acts as an antigen depot.

Authors:  G A Wilbanks; J W Streilein
Journal:  Reg Immunol       Date:  1989 Nov-Dec

4.  The immune response and the eye. III. Anterior chamber-associated immune deviation can be adoptively transferred by serum.

Authors:  T A Ferguson; J D Hayashi; H J Kaplan
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

5.  The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber-associated immune deviation (ACAID).

Authors:  T A Ferguson; J C Waldrep; H J Kaplan
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

6.  Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune deviation.

Authors:  H J Kaplan; J W Streilein
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

7.  Uveoscleral drainage of aqueous humour.

Authors:  R C Tripathi
Journal:  Exp Eye Res       Date:  1977       Impact factor: 3.467

8.  Ocular immune responses. I. Priming of A/J mice in the anterior chamber with azobenzenearsonate-derivatized cells induces second-order-like suppressor T cells.

Authors:  R P Wetzig; C S Foster; M I Greene
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

9.  Regulation of the systemic immune response by visible light and the eye.

Authors:  T A Ferguson; J D Hayashi; H J Kaplan
Journal:  FASEB J       Date:  1988-11       Impact factor: 5.191

10.  Induction of anterior chamber-associated immune deviation requires an intact, functional spleen.

Authors:  J W Streilein; J Y Niederkorn
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  14 in total

1.  The plasticity of regulatory T cell function.

Authors:  Meenu R Pillai; Lauren W Collison; Xiaohua Wang; David Finkelstein; Jerold E Rehg; Kelli Boyd; Andrea L Szymczak-Workman; Teresa Doggett; Thomas S Griffith; Thomas A Ferguson; Dario A A Vignali
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

Review 2.  Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells.

Authors:  Thomas S Griffith; Thomas A Ferguson
Journal:  Immunity       Date:  2011-10-28       Impact factor: 31.745

Review 3.  Impact of sepsis on CD4 T cell immunity.

Authors:  Javier Cabrera-Perez; Stephanie A Condotta; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Leukoc Biol       Date:  2014-05-02       Impact factor: 4.962

4.  Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent.

Authors:  Prajwal Gurung; Deepa Rai; Stephanie A Condotta; Jeffrey C Babcock; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Immunol       Date:  2011-07-25       Impact factor: 5.422

5.  Trauma patients' elevated tumor necrosis related apoptosis inducing ligand (TRAIL) contributes to increased T cell apoptosis.

Authors:  Gautam Bandyopadhyay; Paul E Bankey; Carol L Miller-Graziano
Journal:  Clin Immunol       Date:  2012-08-03       Impact factor: 3.969

6.  Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in Mice.

Authors:  Megan Rogge; Xiao-Tang Yin; Lisa Godfrey; Priya Lakireddy; Chloe A Potter; Chelsea R Del Rosso; Patrick M Stuart
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

Review 7.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

Review 8.  T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Authors:  Stephanie A Condotta; Javier Cabrera-Perez; Vladimir P Badovinac; Thomas S Griffith
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  Influence of CD8+ T regulatory cells on intraocular tumor development.

Authors:  Kyle C McKenna; Dana M Previte
Journal:  Front Immunol       Date:  2012-09-28       Impact factor: 7.561

10.  TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.

Authors:  Kathrin Steinwede; Stefanie Henken; Jennifer Bohling; Regina Maus; Bianca Ueberberg; Christina Brumshagen; Erik L Brincks; Thomas S Griffith; Tobias Welte; Ulrich A Maus
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.